Free Trial
→ First Look: Elon’s “Starphone” (From Stansberry Research) (Ad)tc pixel
NASDAQ:RZLT

Rezolute Q1 2027 Earnings Date & Estimates

Rezolute logo
$4.87 +0.23 (+4.96%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$4.87 +0.00 (+0.06%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rezolute is expected to report Q1 2027 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q1 2027
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Rezolute in Q1 2027

Rezolute is expected to post earnings of -$0.18 per share on revenue of $1.12 million. In the same quarter a year earlier Rezolute reported -$0.18 per share. Rezolute last reported on September 24, 2026, posting -$0.20 per share and missing the -$0.1479 consensus estimate. Rezolute has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.18
Expected Revenue
$1.12 million
Prior-Year EPS
-$0.18

Recent Track Record

Last Reported
Q4 2026
Last Quarter EPS
-$0.20 (Missed by -$0.0522)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q1 2027 Call

Rezolute Q1 2027 Earnings FAQ

Rezolute (NASDAQ:RZLT) is estimated to report Q1 2027 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Rezolute's Q1 2027 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Rezolute to post earnings of -$0.18 per share for Q1 2027.

The consensus revenue estimate for Rezolute is $1.12 million for Q1 2027.

Rezolute Earnings Headlines

Rezolute, Inc. (RZLT) Latest Press Releases & Corporate News - Yahoo Finance
October 8 at 6:40 PM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RZLT/press-releases/
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Moderate Buy" from Analysts
October 8 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098883
Look at Elon’s face after meeting with China
Elon Musk recently met with Chinese President Xi Jinping, and a former Wall Street Journal Personal Finance Expert says the agenda could have major implications for the U.S. economy. The analysis outlines five steps Americans may want to consider before November 12, 2026.tc pixel
 |  International Living (Ad)
Cantor Fitzgerald upgrades Rezolute to overweight from neutral
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/cantor-fitzgerald-upgrades-rezolute-to-overweight-from-neutral/ar-AA2dHoOU
Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/rezolute-upgraded-at-cantor-on-pre-bla-meeting-for-ersodetug/ar-AA2dHue3
Rezolute (NASDAQ:RZLT) Stock Price Expected to Rise, Citizens Jmp Analyst Says
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31091959
See More Rezolute Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rezolute? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rezolute and other key companies, straight to your email.

About Rezolute

Rezolute (NASDAQ:RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.

Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar. RZ358 has been evaluated in clinical studies involving children and adults with the condition.

The company has also advanced RZ402, an investigational oral plasma kallikrein inhibitor being developed for diabetic macular edema, a vision-threatening complication of diabetes. Rezolute’s pipeline reflects its broader goal of developing treatments that address significant unmet needs in metabolic and related diseases. The company is headquartered in Redwood City, California, and is led by President and Chief Executive Officer Nevan Elam.

View Rezolute Profile
Earnings Tools